VIYASH Viyash Scientific Q3 FY26 results (Oct–Dec 2025) and concall
Viyash Scientific Limited reported strong Q3 FY26 results, with significant revenue and EBITDA growth driven by broad-based participation across segments and geographies. The company achieved substantial margin expansion and strengthened its balance sheet, despite one-time merger-related and tax expenses. Management expressed confidence in sustaining 20% EBITDA margins and outlined strategic growth drivers including companion animals and CDMO.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue up 1.2%, net profit down 100.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 42 | 338 | 42 | 328 | 340 +710% | 342 +1% |
| EBITDA | -2 | 58 | -3 | 49 | 52 +2700% | 70 +21% |
| Net profit | 4 | 51 | 4 | 17 | 23 +475% | 0 −100% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
